BeiGene (BGNE)
NASDAQ:BGNE

BeiGene Stock Analysis & Ratings

BeiGene Stock Analysis Overview

Smart Score
6
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The BeiGene stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

BGNE

BGNE Stock Stats

Previous Close$251.37
Open$247
Bid230 x 1
Ask247 x 6
Today’s Range$243.88 - $254.228
52-Week Range$220.04 - $426.56
Volume310.08K
Average Volume266.90K
Market Cap$25.75B
Beta0.71
P/E RatioN/A
EPS0.00
Earnings DateMar 02, 2022

Company Description

BeiGene

BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
Sector
Healthcare
Industry
Biotechnology
CEO
John V. Oyler
Employees
7,600
Website
www.beigene.com
ISIN
US07725L1026
Address
c/o Mourant Governance Services (Cayman) Limited, Grand Cayman, KY1-1108, KY

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

BeiGene News


BGNE FAQ

What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $220.04 and its highest was $426.56 in the past 12 months.
    What is BeiGene’s market cap?
    BeiGene’s market cap is $25.75B.
      What is BeiGene’s price target?
      The average price target for BeiGene is $406.60. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $427.00 ,the lowest forecast is $360.00. The average price target represents 61.70% Increase from the current price of $251.45.
        What do analysts say about BeiGene?
        BeiGene’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
          When is BeiGene’s upcoming earnings report date?
          BeiGene’s upcoming earnings report date is Mar 02, 2022 which is in 37 days.
            How were BeiGene’s earnings last quarter?
            BeiGene released its earnings results on Nov 04, 2021. The company reported -$4.46 earnings per share for the quarter, beating the consensus estimate of -$4.7 by $0.24.
              Is BeiGene overvalued?
              According to Wall Street analysts BeiGene’s price is currently Undervalued.
                Does BeiGene pay dividends?
                BeiGene does not currently pay dividends.
                What is BeiGene’s EPS estimate?
                BeiGene’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does BeiGene have?
                BeiGene has 102,420,000 shares outstanding.
                  What happened to BeiGene’s price movement after its last earnings report?
                  BeiGene reported an EPS of -$4.46 in its last earnings report, beating expectations of -$4.7. Following the earnings report the stock price went down -2.336%.
                    Which hedge fund is a major shareholder of BeiGene?
                    Among the largest hedge funds holding BeiGene’s share is PRIMECAP Management Co. It holds BeiGene’s shares valued at 1B.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis